This excerpt taken from the EW 8-K filed Jun 6, 2005.
About 3F Therapeutics
3F Therapeutics, Inc., (3F) located in Lake Forest, Calif., is a privately held company formed to develop, manufacture and market innovative devices for the cardiac
surgeon. 3F Therapeutics patented technologies, based on a tubular valve concept, lend themselves to minimally invasive surgery (MIS) and will be applicable to both aortic and mitral valve replacement. 3Fs focus on the cardiac surgeon is based on the belief that the vast majority of heart valve replacement procedures will continue to be performed by the cardiac surgeon in the operating room. For more information on 3F, visit the web site at www.3ftherapeutics.com.
Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, Fogarty, PERIMOUNT, and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the U.S. Patent and Trademark Office. LifeStent is a trademark of Edwards Lifesciences AG and is registered in the U.S. Patent and Trademark Office.
This news release includes forward-looking statements that involve risks and uncertainties including those related to the success of preclinical and clinical studies of percutaneous heart valve replacement, the opportunity for, and the potential size of, the catheter-based heart valve repair and replacement market, the ability of this transaction to further strengthen the companys global leadership and, more generally, other risks detailed in the companys filings with the Securities and Exchange Commission. These forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.